Both the anti-TNF-α monoclonal antibodies infliximab and adalimumab and other biological therapies used in treating patients with IBD, such as ustekinumab and vedolizumab, can reduce intestinal dysbiosis by modifying the composition and function of the microbiota [61,62,63,64]. This evidence concerns the gene TNF and inflammatory bowel disease.